# IMPACT-AML: Randomized Pragmatic Clinical Trial for Relapsed or Refractory AML

> **NCT06418776** · PHASE3 · RECRUITING · sponsor: **National Research Center for Hematology, Russia** · enrollment: 198 (estimated)

## Conditions studied

- Refractory Acute Myeloid Leukemia
- Early Relapses of Acute Myeloid Leukemia

## Interventions

- **OTHER:** Intensive therapy
- **OTHER:** Low intensity therapy

## Key facts

- **NCT ID:** NCT06418776
- **Lead sponsor:** National Research Center for Hematology, Russia
- **Sponsor class:** NETWORK
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-04-01
- **Primary completion:** 2027-04
- **Final completion:** 2029-05
- **Target enrollment:** 198 (ESTIMATED)
- **Last updated:** 2024-05-17

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06418776

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06418776, "IMPACT-AML: Randomized Pragmatic Clinical Trial for Relapsed or Refractory AML". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT06418776. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*